MAP2K7 and melanoma: Treatment with digitoxin plus MEK inhibitor significantly reduced NAD+ levels in melanomas from all 3 patients compared with control mice, significantly more than MEK inhibitor alone in 2 out of 3 melanomas, and significantly more than digitoxin alone in 2 out of 3 melanomas (Fig. 6g).